Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort
Parul Tandon, Yvette Leung, Ryan Ward, Abhinav Wadhwa, Jessica Weiss, Ruth Moulson, Christopher Pettengell, Robert Battat · 2026
Read Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort by Parul Tandon, Yvette Leung, Ryan Ward, Abhinav Wadhwa, Jessica Weiss, Ruth Moulson, Christopher Pettengell, Robert Battat (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13639363.txt.
Description
A peer-reviewed research article from Europe PMC (2026). Background and AimsBowel urgency is a burdensome symptom of inflammatory bowel disease (IBD) that greatly impacts quality of life. This study evaluated vedolizumab effectiveness on bowel urgency in Canadian patients with ulcerative colitis (UC) and Crohn’s disease (CD).MethodsAdults with moderately to severely active UC or CD with baseline Urgency Numeric Rating Scale (UNRS) scores enrolled in the Canadian Patient Support Program (July 2024–March 2025) were included. Bowel urgency and clinical endpoints were evaluated at 2, 6, and 14 weeks.
Catalog record
| CREATOR | Parul Tandon, Yvette Leung, Ryan Ward, Abhinav Wadhwa, Jessica Weiss, Ruth Moulson, Christopher Pettengell, Robert Battat |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |